文献速递肾小球疾病

尿足细胞丢失与原发性肾病综合征治疗反应相关

Urinary Podocyte Loss is Associated With Treatment Response in Patients With Primary Nephrotic Syndrome.
PubMed 文献 · Kidney Int Rep · 2025-11-17

结果显示患者尿足细胞增多,且随蛋白尿变化;在微小病变/局灶节段性肾小球硬化免疫抑制治疗患者中,基线尿足细胞可区分4周早期与延迟应答,而蛋白尿和血清白蛋白不能。

要点

  • 原发性肾病综合征患者尿足细胞较健康对照增多,完全蛋白尿缓解后正常化。
  • 在微小病变/局灶节段性肾小球硬化免疫抑制治疗者中,基线尿足细胞可区分4周早期与延迟应答。
  • 膜性肾病患者基线低尿足细胞水平与自发缓解相关。

核心结论

  • 原发性肾病综合征患者尿足细胞较健康个体增多,定量检测可能具有预后价值。

研究设计与样本

  • 纳入21例对照和59例原发性肾病综合征患者,其中微小病变8例、局灶节段性肾小球硬化9例、膜性肾病42例。
  • 微小病变与局灶节段性肾小球硬化被视为同一疾病实体合并分析,记录基线临床和随访数据。
  • 收集尿沉渣,用足细胞特异性标记染色并通过荧光激活细胞分选(FACS)分析。

主要发现

  • 微小病变/局灶节段性肾小球硬化患者部分缓解率24%、完全缓解率59%,中位随访12.9个月,所有患者均接受免疫抑制治疗。
  • 膜性肾病患者部分缓解率64%、完全缓解率19%,中位随访15.5个月,多数患者接受免疫抑制治疗。
  • 原发性肾病综合征患者尿足细胞水平较对照升高,重复检测显示尿足细胞随蛋白尿变化,完全蛋白尿缓解后正常化。
  • 在治疗应答的微小病变/局灶节段性肾小球硬化免疫抑制治疗患者中,基线尿足细胞显著区分4周早期与延迟应答者,而蛋白尿和血清白蛋白无此区分作用。
  • 在仅对症治疗的膜性肾病患者中,基线低尿足细胞水平与自发缓解相关。

临床怎么用

  • 对原发性肾病综合征患者可考虑检测尿足细胞,辅助预测免疫抑制治疗早期应答。
  • 在微小病变/局灶节段性肾小球硬化患者中,基线尿足细胞或有助于识别4周延迟应答者。
  • 在膜性肾病患者中,基线低尿足细胞水平或提示自发缓解可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The disease course of primary nephrotic syndrome (PNS) is highly variable, and is difficult to predict at onset. PNS is characterized by podocyte injury and loss. We hypothesized that measurement of urinary podocyte loss is associated with treatment response in patients with PNS. METHODS: We included 21 controls, and 59 patients with PNS (minimal change disease [MCD], n =8; focal segmental glomerulosclerosis [FSGS], n = 9; membranous nephropathy [MN]. n = 42). MCD and FSGS were considered manifestations of the same disease entity, and analyzed as one group. Patients' baseline clinical and follow-up data were recorded. Urinary sediments were collected and stained for podocyte-specific markers, and analyzed using fluorescence-activated cell sorting (FACS). RESULTS: In patients with MCD/FSGS, the respective partial and complete remission rates were 24% and 59% during a median follow-up of 12.9 months, and all patients received immunosuppressive treatment. In patients with MN, the respective partial and complete remission rates were 64% and 19% during a median follow-up of 15.5 month, and the majority of patients received immunosuppressive treatment. Patients with PNS had elevated levels of podocyturia when compared with controls, and repeat measurements revealed that podocyturia follows proteinuria course over time, normalizing following complete proteinuria remission. In treatment-responsive immunosuppresive-treated patients with MCD/FSGS, podocyturia at baseline significantly differentiated between early and late treatment responders at 4 weeks, contrary to proteinuria and serum albumin. In symptomatically treated patients with MN, low levels of podocyturia at baseline were associated with spontaneous remission. CONCLUSION: Patients with PNS have increased podocyturia compared with healthy individuals. Quantitative detection of podocyturia may have prognostic relevance in patients with PNS.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. van den Berge BT, Jansen J, Leusink Q, et al. Urinary Podocyte Loss is Associated With Treatment Response in Patients With Primary Nephrotic Syndrome. Kidney Int Rep. 2025. PMID: 41542111. doi:10.1016/j.ekir.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。